Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$40.34 USD

40.34
1,846,760

+0.08 (0.20%)

Updated Aug 12, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised

by Zacks Equity Research

Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.

Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.

Ekta Bagri headshot

Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?

by Ekta Bagri

While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.

Ekta Bagri headshot

Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback

by Ekta Bagri

Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.

Here's Why GSK (GSK) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.

GSK (GSK) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 9% and 4.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

by Ekta Bagri

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Here's Why GSK (GSK) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Sundeep Ganoria headshot

Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

GSK Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.

GSK (GSK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review

by Zacks Equity Research

GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Mark Vickery headshot

Top Research Reports for Apple, Lowe's & Shopify

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Lowe's Companies, Inc. (LOW) and Shopify Inc. (SHOP), as well as two micro-cap stocks MIND Technology, Inc. (MIND) and Moving iMage Technologies, Inc. (MITQ).

Sundeep Ganoria headshot

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

by Sundeep Ganoria

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.

Why GSK (GSK) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?

by Zacks Equity Research

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates make the stock attractive

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Ekta Bagri headshot

Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?

by Ekta Bagri

While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.

GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac

by Zacks Equity Research

GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.

Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More

by Zacks Equity Research

GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.

CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine

by Zacks Equity Research

If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.